MUTATIONS IN THE P53 GENE ARE FREQUENT IN PRIMARY, RESECTED NON-SMALL-CELL LUNG-CANCER

被引：0
|
作者：
CHIBA, I
TAKAHASHI, T
NAU, MM
DAMICO, D
CURIEL, DT
MITSUDOMI, T
BUCHHAGEN, DL
CARBONE, D
PIANTADOSI, S
KOGA, H
REISSMAN, PT
SLAMON, DJ
HOLMES, EC
MINNA, JD
机构：
[1] NATL NAVAL MED CTR, NCI, NAVY MED ONCOL BRANCH, BLDG 8, ROOM 5101, BETHESDA, MD 20814 USA
[2] UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20814 USA
[3] JOHNS HOPKINS UNIV HOSP, CTR ONCOL, BALTIMORE, MD 21205 USA
[4] UNIV CALIF LOS ANGELES, SCH MED, DEPT SURG, LOS ANGELES, CA 90024 USA
[5] UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA
来源：
ONCOGENE | 1990年 / 5卷 / 10期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：1603 / 1610
页数：8
相关论文
共 50 条
  • [31] p53 Mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study
    Ahrendt, SA
    Hu, YC
    Buta, M
    McDermott, MP
    Benoit, N
    Yang, SC
    Wu, L
    Sidransky, D
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (13) : 961 - 970
  • [32] Characteristics of P53 gene mutations in Polish non small cell lung cancer (NSCLC) patients
    Skrzypski, M
    Szymanowska, A
    Jassem, E
    Niklinski, J
    Jakobkiewicz-Banecka, J
    Dziadziuszko, R
    Kobierska-Gulida, G
    Rzyman, W
    Limon, J
    Jassem, J
    LUNG CANCER, 2005, 49 : S145 - S145
  • [33] p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer
    Vega, FJ
    Iniesta, P
    Caldes, T
    Sanchez, A
    Lopez, JA
    deJuan, C
    DiazRubio, E
    Torres, A
    Balibrea, JL
    Benito, M
    BRITISH JOURNAL OF CANCER, 1997, 76 (01) : 44 - 51
  • [34] Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma
    T. Iizasa
    Takehiko Fujisawa
    Yukio Saitoh
    Kenzo Hiroshima
    Hidemi Ohwada
    Cancer Immunology, Immunotherapy, 1998, 46 : 345 - 349
  • [35] Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma
    Iizasa, T
    Fujisawa, T
    Saitoh, Y
    Hiroshima, K
    Ohwada, H
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 46 (06) : 345 - 349
  • [36] SITES OF FIRST DISTANT RECURRENCE IN RESECTED NON-SMALL-CELL LUNG-CANCER
    URSCHEL, JD
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1995, 110 (01): : 286 - 286
  • [37] BCL-2 PROTEIN - A PROGNOSTIC FACTOR INVERSELY CORRELATED TO P53 IN NON-SMALL-CELL LUNG-CANCER
    FONTANINI, G
    VIGNATI, S
    BIGINI, D
    MUSSI, A
    LUCCHI, M
    ANGELETTI, CA
    BASOLO, F
    BEVILACQUA, G
    BRITISH JOURNAL OF CANCER, 1995, 71 (05) : 1003 - 1007
  • [38] P53 - A FREQUENT TARGET FOR GENETIC ABNORMALITIES IN LUNG-CANCER
    TAKAHASHI, T
    NAU, MM
    CHIBA, I
    BIRRER, MJ
    ROSENBERG, RK
    VINOCOUR, M
    LEVITT, M
    PASS, H
    GAZDAR, AF
    MINNA, JD
    SCIENCE, 1989, 246 (4929) : 491 - 494
  • [39] Survival, in operable non-small-cell lung cancer:: Role of p53 mutations, tobacco smoking and asbestos exposure
    Sioris, T
    Husgafvel-Pursiainen, K
    Karjalainen, A
    Anttila, S
    Kannino, A
    Salo, JA
    Perhoniemi, V
    Heikkilä, L
    Vainio, H
    INTERNATIONAL JOURNAL OF CANCER, 2000, 86 (04) : 590 - 594
  • [40] Microsatellite alterations and p53, TGFβRII, IGFIIR and BAX mutations in sporadic non-small-cell lung cancer
    Caligo, MA
    Ghimenti, C
    Marchetti, A
    Lonobile, A
    Buttitta, F
    Pellegrini, S
    Bevilacqua, G
    INTERNATIONAL JOURNAL OF CANCER, 1998, 78 (05) : 606 - 609
12345